BHCM
IOVA icon

Brevan Howard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Brevan Howard Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,353
Closed -$282K – 2309
2026
Q1 		$282K Buy
+80,353
New +$257K ﹤0.01% 1662

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Brevan Howard Capital Management's IOVA Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 81,981 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #1632 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in IOVA as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in IOVA in Q2 2022 and has held it in 16 quarters since. The position peaked at $10.4M in Q2 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Brevan Howard Capital Management held 81,981 shares of Iovance Biotherapeutics worth $341K as of Q2 2026.
  • Iovance Biotherapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1632 holding.
  • Brevan Howard Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Brevan Howard Capital Management's Iovance Biotherapeutics position peaked at $10.4M in Q2 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.